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An intravenous drug user was found to be dually infected with two genetically and phylogenetically distinct human
immunodeficiency virus type 1 (HIV-1) subtype B strains (designated groups I and II). Viral isolation revealed a simultaneous
copassaging of two strains in PBMC. The culture of viral strains on monocytes and monocyte-derived macrophages
preferentially segregated the two viral strains. The group I strain utilized CXCR4 and group II used CCR5 coreceptor for entry.
Sequencing of .100 clones from uncultured PBMC consistently showed the predominance of group II virus in vivo.
Importantly, the group II virus alone could not productively infect PBMC, but when used together with group I virus for
infection, the group II virus regained its high replication potential and predominance in cultured PBMC. These data are the
first to provide direct evidence in favor of molecular and biological interaction between two infecting strains in a coinfected
patient and show their differential pathogenic effects, tropism, and modes of entry. In addition, our data provide the first
evidence for synergism between these two strains. Cumulatively, these data emphasize that in order to clearly interpret
coreceptor usage, biological segregation of viral strains from primary isolates in vitro may be imperative. © 2000 Academic Press
o
sINTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) displays
marked genetic heterogeneity in vivo (Coffin 1986; Hahn
et al., 1986; Meyerhans et al., 1989). A highly error-prone
reverse transcriptase (Hu and Temin, 1990; Preston et al.,
1988; Roberts et al., 1988) and recombination (Jin et al.,
994; Sabino et al., 1994; Robertson et al., 1995; Clavel et
l., 1989) are the major variables in creating mutations
uring retrovirus replication. Recombination is common
n geographical regions where multiple HIV-1 subtypes
ocirculate (Jin et al., 1994; Sabino et al., 1994; Robertson
t al., 1995; Clavel et al., 1989) and also in coinfected
umans (Saksena et al., 1997; Zhu et al., 1995; Butto et
l., 1997) and in chimpanzees experimentally infected
ith two or more HIV strains/subtypes (Wei and Fultz,
998).
Our understanding of the global molecular epidemiol-
gy of HIV-1 infections has improved substantially in
ecent years, but the remarkable genetic diversity espe-
ially in the envelope gene has revealed that the HIV
andemic has grown immensely and the global dis-
ersal of HIV strains is confounded by growing evidence
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (Int 1 61-2) 9639 7431. E-mail: Nitin_Saksena@wmi.
syd.edu.au.
105f mixed and recombinant infections with diverse HIV-1
ubtypes (Zhu et al., 1995; Butto et al., 1997; Rayfield et
al., 1988; Evans et al., 1988). It is thus vital to understand
the role of mixed infections, which is a prerequisite for
recombination, because ultimately the efficacy of HIV-1
vaccines will depend on the molecular nature of infecting
strains.
Genetic variation in the envelope gene has been cor-
related with differential entry of HIV-1 strains (Xiao et al.,
1998). CCR5 is the major coreceptor for viral entry of
non-syncytium-inducing (NSI) HIV strains into primary
CD4 lymphocytes and macrophages, but not T-cell lines
(Alkhatib et al., 1996; Deng et al., 1996). By contrast, the
T-tropic HIV strains use CXCR4 as entry coreceptor (Feng
et al., 1996), while dual-tropic strains use both CCR5 and
CXCR4 (Yi et al., 1998). Recent data indicate that HIV
strains differ in how they utilize chemokine coreceptors
for entry and their ability differs in mediating entry de-
pending on the cell type (Yi et al., 1998). In addition, the
expression of chemokine receptors on the cell surface at
various stages of cellular differentiation, such as mono-
cyte to monocyte-derived macrophages (MDM) in vitro,
may also modulate chemokine receptor usage by the
virus (Tuttle et al., 1998).
Most of the recent data on the entry of HIV-1 and HIV-2
strains using a broad range of chemokine coreceptors
has been done using primary viral isolates (Deng et al.,
0042-6822/00 $35.00
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c106 WANG ET AL.1996; Pohlmann et al., 1998; Owen et al., 1998; McKnight
et al., 1999; Momer et al., 1993) without giving much
significance to viral quasispecies present in vivo and
also to the possibility of passaging of multiple strains in
vitro. Thus, the interpretation of these published data on
viral entry may be valid only in part. Our data unambig-
uously demonstrate that in order to clearly dissect out
viral entry and tropism mechanisms of primary viral iso-
lates, prior genotypic determination and biological seg-
regation of strains present in vivo and in vitro are
needed. This will clarify some controversial issues relat-
ing to viral entry and tropism during HIV disease pro-
gression.
Coinfected individuals provide the best medium to
study both biological and molecular interactions be-
tween viral strains. It is thus vital to understand the
effects these biological and molecular interactions be-
tween HIV-1 strains may have either on the disease
outcome or on the biological properties of viral strains,
such as antigenicity, immune escape, cell tropism,
pathogenesis, virulence, and viral entry. To date, very
little is known about the additive and synergistic effects
of coinfection and subsequent recombination between
HIV-1 strains in dually and/or multiply infected individu-
als. The role of different infecting strains in coinfected
patients and the molecular and biological interactions
between them that may govern their pathogenesis re-
main obscure. Although recombination between different
subtypes has been thought to result in viral strains with
renewed and/or altered pathogenic potential (Carr et al.,
1996), no biological evidence is available to demonstrate
this phenomenon. Our study provides evidence showing
that recombination between viral strains within an indi-
vidual (979) may play some part in switching viral tropism
in vitro. Most importantly, these data provide the first
biological and molecular evidence in favor of interaction
between two HIV-1 strains in a coinfected patient and its
role in HIV pathogenesis.
RESULTS
PCR, cloning, sequencing, and phylogeny of the env
V3/gp120 region and Vpr sequences showing the
presence of two distinct groups of viruses
in patient 979
We successfully amplified the env V3 region, C2–V5
region, gp120, and Vpr gene from the genomic DNA
FIG. 1. (a) Peptide sequence alignment of the env V3 region clones s
group I and group II) in a patient’s uncultured PBMC. A total of 100 clo
death—were sequenced. Sequences from two time points revealed hig
point were included in biological analysis. Because of high homoge
differences in the variable regions (VI–V5) of env gp120 between group I
variability in VI–V5 regions between group I and group II is indicated
segregation of two groups of HIV-1 strains from patient’s uncultured
Strains ANT 70, subtype O; ELI, subtype D; BZ163A, subtype A; UG268A, subt
SF2, subtype B were retrieved from the Los Alamos HIV database (Los Alamobtained from infected uncultured PBMC collected at
two different time points. One hundred V3 region clones,
15 full-length gp120 region clones, and 14 Vpr gene
clones were sequenced (Figs. 1a, 1b, and 2a).
Based on the V3 region, two groups (group I and group
II) were identified, with intragroup variation of ,3% and
intergroup divergence of 20–25% at the peptide level (Fig.
1a). The V3 loop in group I sequences (19% of the total
population in vivo) was 38 amino acids long due to a
3-residue insertion (GHI) resulting in a unique motif, CI
GHI GPGRAL. Also, an additional cysteine at position
113 from the first Cys residue of the V3 loop was also a
haracteristic feature of group I sequences in vivo (Wang
et al., 1998). Additionally, all the clones from group I
showed a deletion of asparagine (N) (forming an N-
linked glycosylation site) located at position 125 from
the second cysteine residue of the V3 loop (Fig. 1a). In
contrast, the group II clones (81% of the total population
in vivo) revealed a V3 loop consisting of 34 residues as
a consequence of a threonine residue deletion at posi-
tion 21 (Fig. 1a). Further, a detailed comparison of con-
sensus gp120 sequences of each group revealed a 15.2
to 51.7% difference in the V1–V5 regions (Fig. 1b).
Similarly, groups I and II could also be segregated
based on Vpr gene sequences. The peptide diversity
range between them was on the order of 9–12% with
intragroup diversity of ,4%. The Vpr gene in group II was
characterized by group-specific changes at residues 28,
37, 41, 55, 70, and 77, whereas the group I gene was
characterized by changes at residues 41 and 85 (Fig. 2a).
Further, the phylogenetic comparisons of the env V3
region and the Vpr gene with other reference HIV-1
subtypes (Los Alamos HIV Database, Los Alamos, NM)
confirmed the validity of coinfection in patient 979 (Figs.
1c and 2b). The more numerous group II clones clustered
together and the smaller set of group I clones stably
separated from group II. Interestingly, the group I se-
quences formed a monophyletic group with HIV-1 strains
from a coinfected Australian patient (Zhu et al., 1995).
Overall, these analyses tend to demonstrate a somewhat
closer relationship to the reference B sequences.
Infection of different primary cell types with a
combination of group I and II HIV strains
The infectious potential and tropism of viral strains,
when present in combination in patients’ PBMC, were
the presence of two distinct groups of HIV-1 sequences (designated
m two time points—one 9 months before death and one close to her
group homogeneity in the V3 region; hence only strains from one time
nly 16 clones representing groups I and II are shown. (b) Genetic
oup II strains derived from uncultured PBMC of patient 979. The overall
figure. (c) Phylogenetic tree based on the env V3 region showing the
Sequences used in phylogenetic reconstructions were gap-stripped.howing
nes fro
h intra
neity o
and gr
in the
PBMC.
ype F; SMI45A, subtype C; LBV217, subtype G; SF1703, subtype E; and
os, NM).
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108 WANG ET AL.assessed first by growing the heterogenous virus isolate
from the patient on the PBMC of a healthy donor. The
virus grew to high levels in PBMC as confirmed by p24
antigen assay. The env V3 region sequence determina-
ion of the viral strains from cultured PBMC clearly
howed the successful copassaging of group I and
roup II viruses, which was further evident from their
enetic (Fig. 3a) and phylogenetic segregation (Fig. 3b).
urther sequencing analysis showed the dominance of
roup II viruses in cultured PBMC, which comprised 12
f 15 clones (Fig. 3a).
Following successful isolation of viral strains in PBMC,
his virus stock was used to infect monocytes, MDM, and
-lymphocytes. Viral strains grew actively on monocytes
nd T-lymphocytes, but to moderately poor levels on
acrophages as confirmed by extracellular p24 antigen
iters measured on days 0, 3, 7, 10, and 14 postinfection
Fig. 4a). AluI digestion of the env C2–V5 fragment of
onocytes, MDM, and T-lymphocytes from the last time
oint (day 14) revealed that there was preferential/inde-
endent biological segregation of group I and II strains
n monocytes and macrophages (Fig. 4b). A total of 17
lones from monocytes and 14 clones from MDM
howed distinct patterns of AluI digestion (Fig. 4b). Se-
uence determination of env C2–V5 region clones, char-
cterized by cell-specific changes, further confirmed the
referential passaging of group I viral strains on mono-
FIG. 2. (a) Peptide sequence alignment of the vpr gene clones deri
roups of viral strains in patient 979. Dissimilarity between group I and
train was used as a prototype. (b) Phylogenetic tree confirming the seg
lones.ytes and group II viruses on MDM (Fig. 4c). By contrast,
ultured T-lymphocytes harbored both groups as con-
m
oirmed by both AluI restriction digestion pattern and se-
uencing of the env gene clones (Figs. 4b and 4c).
verall, these sequence changes may form the basis for
iral tropism of group I and II strains.
nfection of different cell types individually with group
and II viral strains and their tropism: Evidence for
iological interaction between infecting strains and
ynergism
Followed by the biological segregation of group I and
I viral strains on monocytes and MDM, viral strains were
epeatedly passaged several times on these cell types to
onfirm the validity of their biological separation, along
ith their verification on PBMC of healthy donors. The H9
ells (a T-cell line) were briefly used because of their
xpression of CXCR4. The passaging on each cell type
as controlled by PCR, AluI restriction digestion, and
equencing of the C2–V5 env gene fragment (data not
hown). We observed that the reinfection with the virus
erived from monocytes (group I) could easily infect the
BMC of healthy donors (Fig. 5a), whereas the group II
irus derived from MDM, which constituted the predom-
nant population in vivo, could only nonproductively infect
BMC of healthy donors (Fig. 5a). Interestingly, when
iral strains were copassaged with the same m.o.i. of
0,000 RT per group into PBMC, the group II strains from
m proviral DNA from uncultured PBMC showing the presence of two
I sequences is depicted on the right-hand side of the figure. HIV-1 SF-2
n of two groups of sequences based on the sequences of the vpr geneved fro
group Iacrophages gained predominance in vitro, forming 80%
f the total population (Fig. 5b). These data show that the
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111PATHOGENIC MECHANISMS IN HIV COINFECTIONgroup II viral strains could productively infect the PBMC
of healthy donors only when the group I strain was
present (Figs. 5a and 5b). Otherwise, they remain biolog-
ically different when grown separately, with group I virus
being monocyto-tropic and group II being macrophage-
tropic (Figs. 4a, 4b, and 4c). In addition, these data show
that although the replication potential of viral strains
increased only marginally, the increase in cytopathic
effects was concomitant with the dominance of group II
virus (Figs. 6d–6i). The group I and group II viral strains
always copassaged on primary T-lymphocytes, and the
group II viral strain could gain entry into the T-cells only
when present with group I virus, suggesting a helper
virus effect or synergistic interaction between group I
and II viruses. These results are unique in showing that
although the two strains have their individual tropism,
their overall tropism is influenced by each other in vitro.
This could be attributed to molecular differences be-
tween the two groups in the env gene, which may mod-
ulate their biological properties and infectious potential.
Viral phenotype
The clones from both groups demonstrated low net V3
loop charges (Fig. 1a), which is usually associated with
the non-syncytium-inducing phenotype of HIV strains be-
longing to subtype B (Fouchier et al., 1992). The confir-
mation of phenotype on the MT-2 cell line showed group
I virus with the syncticium-inducing phenotype and group
II with the NSI phenotype.
Transmission electron microscopy showing
synergistic and additive effects of the combined
presence of two infecting strains
Transmission electron microscopy (TEM) was con-
ducted using PBMC from a healthy donor. To assess the
cytopathic effect of group I and II viruses, the PBMC
were first separately infected with the virus derived from
monocytes and macrophages. Following the individual
assessment of cytopathic effect of group I and II viruses,
they were combined and passaged into PBMC and the
synergism and additive effects were recorded. We ob-
served no cytopathic effect of group II virus alone on
PBMC and the cells showed intact morphology (Fig. 6a).
It should be noted that the group II virus could not
productively infect PBMC. In contrast, the infection of
PBMC with group I virus revealed occasional syncytia,
but overall there were a large number of healthy cells
with no evidence for apoptosis (Figs. 6b and 6c). How-
ever, when group I and II viral strains were present
together we observed a greater cytopathic effect relative
to effects seen with either group I or group II. There was
higher production of viral particles from the cell surface
(Fig. 6d) with a large number of cells undergoing
apoptosis, cell killing, and increased formation of
multinucleated giant cells (Figs. 6e and 6f). In addition,
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113PATHOGENIC MECHANISMS IN HIV COINFECTIONthe combination of groups I and II induced structural
defects in the Golgi, leading to its distension and prolif-
eration (Figs. 6g, 6h, and 6i), an effect that was com-
pletely absent in the case of group I or II virus-infected
PBMC.
Coreceptor usage and viral entry with group I and II
strains in combination
Viral strains isolated from PBMC of patient 979 con-
sistently revealed dual tropism, which was confirmed
with their coreceptor usage of both CCR5 and CXCR4 on
GHOST cell lines (Fig. 7). CXCR4 usage was further
confirmed using a T-cell line (H9 cells). Interestingly, the
determination of env C2–V5 sequences derived from
GHOST-CD4-CCR51 and GHOST-CD4-CXCR41 cells
howed that group I virus passaged into GHOST-CXCR41
cells and the group II into GHOST-CCR51 cells (Fig. 7).
his was further established by culturing the viruses
erived from monocytes and MDM individually on
HOST cells (Figs. 8a and 8b), confirming the usage of
XCR4 by the viral strain from monocytes and CCR5 by
he virus from macrophages. A detailed molecular com-
arison of the env gene clones derived from GHOST-
CR51 and GHOST-CXCR41 with those of monocyte and
MDM derived env gene clones showed a perfect con-
cordance between group I virus monocytotropism with
CXCR4 usage and group II virus with CCR5 usage and
macrophage tropism in vitro (Figs. 4c and 7).
Alteration in tropism following recombination
Viral strains isolated from uncultured and cultured
PBMC did not show any evidence of recombination, as
FIG. 6. Transmission EM showing the infection of PBMC (day 7) of a
healthy donor with primary isolate from patient 979. (a) Infection of
PBMC of a healthy donor with group II CCR5 using virus derived from
macrophages. Magnification, 37600. Bar, 6 mm. (b and c) Infection of
PBMC with group I CXCR4 using virus derived from monocytes show-
ing a large number of healthy cells and no apoptosis (b) (Magnification,
35700; Bar, 7 mm) and the occasional formation of syncytia (c). The
icture shows an event in which several cells are about to fuse to form
multinucleated giant cell. Interdigitations at the membrane junctions
an be seen (arrow). Magnification, 313,000. Bar, 3 mm. (d) Infection of
PBMC with both group I and II viruses showing the budding and
formation of viral particles from the cell surface (arrow). Magnification,
378,000. Bar, 500 nm. (e and f) Infection of PBMC with both group I and
group II viruses showing cell killing (necrosis) and apoptosis (e) (mag-
nification 35700; Bar, 7 mm) and the formation of giant syncytia with
five nuclei (f) (magnification, 39600; bar, 4 mm). (g) A healthy uninfected
BMC with intact Golgi architecture (arrow). Magnification, 316,800.
ar, 2 mm. (h and i) Infection of PBMC with group I and II viruses
howing the distension and proliferation of Golgi (arrow) (h). Viral
articles can be seen in the vacuolar space (small arrow). Magnifica-
ion, 355,000. Bar, 7 nm. A higher magnification showing the Golgi
roliferation caused by group I and II viruses (arrow) (i). Magnification,
55,000. Bar, 7 nm.
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114 WANG ET AL.verified by the sequencing and AluI restriction digestion
of env C2–V5 region clones. However, a minor population
(clone 9MO-7) derived from cultured monocytes was
confirmed by sequencing and RIP to be a mosaic clone
between group I and II sequences in the env gene (Figs.
9a and 9b), and it was characterized by a distinct AluI
estriction pattern (Fig. 4b). This clone preferentially pas-
aged into monocytes and used only coreceptor CXCR4
or its entry into the cells. Sequencing analyses of this
lone revealed that approximately the V2 and V3 region
f the C2–V5 env gene fragment belonged to group I and
he V4 and V5 region to group II (Figs. 9a and 9b).
hylogenetic trees based on two subfragments (data not
hown) along with the Recombination Identification Pro-
ram (RIP) analysis confirmed that clone 9MO-7 was a
osaic or recombinant sequence.
DISCUSSION
This study demonstrates that coinfection with the di-
ergent HIV-1 strains belonging to subtype B can occur
n an individual, and the infecting variants can behave
ifferently biologically. More importantly, these detailed
nvestigations are the first in providing direct evidence in
avor of molecular and biological interaction and syner-
ism between two infecting HIV-1 strains from a coin-
FIG. 7. Coreceptor usage by group I and group II strains in combin
eceptors at days 3, 7, 10, and 14 postinfection. It is evident that viruses
24 levels at different days in culture supernatant. (Bottom) The resp
GHOST-CD4-CCR51 and GHOST-CD4-CXCR41 cells, respectively. Her
erived from GHOST CD4-CXCR41 cells and group II consensus sequected patient. These viral strains induced differential
iological effects when they were present alone as op-osed to their combined presence. With the help of
etailed in vitro molecular and biological analyses, we
show that the effect of dual infection can be both additive
and to some extent synergistic.
Little is known regarding the pathogenicity and biology
of HIV-1 strains in a dual-infection setting or about the
change in biological properties following recombination.
The global trafficking of diverse HIV subtypes acts as a
facile medium for the spread of dual HIV-1 infections and
the emergence of recombinant strains (Zhu et al., 1995;
utto et al., 1997; Liitsola et al., 1998). Thus in dual
infections, the role of recombination in increasing fitness
and virulence of HIV strains (Carr et al., 1996, Liitsola et
al., 1998), mediating the rescue of defective proviruses
(Clavel et al., 1989; Boulerice et al., 1991), altering phe-
notypes (Groenink et al., 1992; Kellam and Larder, 1995;
Moutouh et al., 1996; Yusa et al., 1997; Myers 1994), and
creating escape variants with novel neutralization
epitopes that may harbor altered tropism (McKnight et
al., 1995) is highly relevant biologically. Similarly, random
assortment of genome segments between human and
animal influenza viruses has been shown to form new
antigenic variants (Webster et al., 1982). Although there
are suggestions in favor of the potential contribution of
additive effects of recombination, there is no biological
n the GHOST cell line transfected with CD4 and different chemokine
bination use CCR5 and CXCR4. Virus replication was measured using
env C2–V5 sequences belonging to groups I and II recovered from
roup I consensus sequence has been compared against sequences
gainst sequences derived from CD4-CCR51 cells.ation o
in com
ectiveevidence to demonstrate that this occurs in HIV. Our
molecular analysis did not show evidence for recombi-
c
s
115PATHOGENIC MECHANISMS IN HIV COINFECTIONnation in vivo, but one of the unique features of these
analyses in vitro is the emergence of a mosaic strain
formed between group I and group II strains from patient
979. This recombinant strain had a preference for mono-
cytes using CXCR4 for viral entry, showing biological
evidence that only following a recombinational event
between both group of viruses was preferential selection
on monocytes observed.
Human macrophages, which are efficiently infectable
with M-tropic HIV-1, also express CXCR4 on their surface.
However, CXCR4 in macrophages is noninteractive for
infection with a majority of X4 utilizing primary HIV-1
isolates (Smyth et al., 1998). Interestingly, in our study we
also observed that despite the availability of CXCR4 on
macrophages, the CXCR4 using virus failed to gain entry
into macrophages. Recently, Lapham et al. (1999) dem-
onstrated that mature macrophages express less high-
molecular-weight CXCR4 than monocytes; the CXCR4 is
hence not available for association with CD4, which may
contribute to the inefficient entry of T-tropic HIV-1 strains.
It has also been shown that monocytes express higher
levels of CXCR4 than CCR5 in early stages of maturation,
whereas there is a dramatic decrease in CXCR4 expres-
sion and marked increase in expression of CCR5 during
differentiation (Tuttle et al., 1998). This could be the
reason that the CXCR4 using strain was preferentially
FIG. 8. (a) Infection of a panel of GHOST cells with group I strain
isolated on monocytes showed exclusive use of coreceptor CXCR4.
CCR3 positivity is due to background expression of CXCR4 in GHOST-
CCR31 cells. (b) The virus isolated on MDM showing exclusive use of
oreceptor CCR5 as measured by extracellular p24 antigen levels
hown on the Y axis.selected on monocytes, but not the CCR5 using strain
from patient 979.Overall, our data on differential coreceptor usage by
two viral strains infecting patient 979 emphasizes that
the previously published data using primary viral iso-
lates, without prior molecular determination of viral qua-
sispecies and their role in viral entry and tropism, may be
only partly valid. To clearly interpret coreceptor usage by
viral strains, their biological segregation may be neces-
sary. Our data, along with other studies, emphasize that
the determinants of tropism and coreceptor usage may
lie in the envelope gene (Fouchier et al., 1992, Shioda et
al., 1991, 1997; Hwang et al., 1991; Rizzuto et al., 1998;
Hoffman et al., 1998). The env V2 and the V3 loops are
known to reside proximal to the chemokine-receptor
binding site, which masks the more conserved elements
of env–gp120, thereby facilitating the presentation of po-
tentially variable epitopes to the immune system (Wyatt
et al., 1998). In addition, specific changes in the V3 region
using chimeric viruses have been shown to be critical in
CCR5 usage (Hung et al., 1999). Importantly, env gene
sequences of the output viral strains derived from T-cells,
monocytes, MDM, GHOST-CD4-CCR51, and GHOST-
CD4-CXCR41 further confirm the presence of critical cell-
specific changes in the env gp120 governing tropism and
coreceptor usage.
In addition to providing the evidence in favor of an
additive effect of two viral strains in modulating viral
pathogenesis, another finding is the demonstration of
synergism between two HIV-1 strains from a coinfected
patient. It has long been speculated that viral synergism
may play some biological role, but lack of data on mo-
lecular and/or biological interactions between HIV-1
strains and a paucity of sufficient biological data from
dually infected patients have hampered our understand-
ing of the pathogenesis of HIV in dual infections. Our
data demonstrate the differential mode of entry of two
viral strains, with group I virus using CXCR4 and group II
using CCR5. Although dual-tropic strains have been
shown to exist (Smyth et al., 1998), it has not been shown
that two distinct HIV-1 strains in a coinfected individual
can behave differently biologically by expressing differ-
ent phenotypes, using distinct tropism mechanisms and
CD4-dependent fusion and entry with CCR5 or CXCR4.
The two strains from the patient, in tandem, behaved like
a dual-tropic strain. In this context, it is important to
mention that dual-tropic strains have been found to be
associated with a rapid total decline in CD41 T-cell
concentration and faster disease progression in 5/5 in-
jecting drug users analyzed by Yu et al. (1998). Thus, the
relatively rapid progression of our patient 979, who died
within 5 years, could be partly attributed to coinfection
with two strains of HIV-1 that were dual-tropic in combi-
nation.
It is interesting to note that the group I virus alone
productively infected PBMC, whereas group II could not.
It was only when group I and II viral strains were present
together that the group II virus could gain entry into the
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116 WANG ET AL.PBMC. Following entry into PBMC, the group II virus
gained predominance in vitro. Similarly, as revealed by
equencing analysis, the group II virus also predomi-
ated in vivo. At this time, the reasons for predominance
f group II virus both in vitro and in vivo remain unclear,
ut our analyses suggest molecular synergism between
IV-1 strains and possibly a helper virus effect. Addition-
lly, transmission electron microscopy demonstrated
hat the two viral strains in combination showed in-
reased production of viral particles, induced massive
poptosis/cell killing, and caused Golgi proliferation and
istension. These effects are significant because they
ere absent when the PBMC were infected individually
ith either group I or group II virus. Together, these data
trongly suggest the active role of viral synergism or a
elper virus effect in modulating the pathogenesis of
FIG. 9. Specific recombinational event in the env C2–V5 clones deriv
group II viruses possibly in the V3 and V4 regions. Clone 9pMo7 (see
a unique digestion pattern that was different from 17 other clones from
II hybrid clone 9PM0-7 showing the breakpoint. RIP was used from thiral strains. Alternatively, we hypothesize that there may
e a complementation of pathogenic determinants of twoiruses in combination, hence the augmentation in viru-
ence.
With the global dispersal of HIV strains, which is con-
ounded by growing evidence of recombinant viruses, it
s vital to understand the role of these mixed infections,
hich is a prerequisite for recombination. Ultimately the
fficacy of HIV-1 vaccines will depend on the molecular
ature of the infecting strains, and the vaccines against
ariants in mixed infections may differ.
MATERIALS AND METHODS
atient
The patient (979) acquired HIV-1 in 1989 via injecting
rug use and died in 1994 with AIDS. At the time of death,
he CD41 T-cell count was 29/ml blood. Blood samples
monocytes showing the event to have occurred between group I and
n Fig. 4b), a hybrid clone, was restricted to monocytes, and it showed
ytes. (b) Recombination identification program analysis of group I and
atabase at the Los Alamos National Laboratory (Los Alamos, NM).ed from
arrow i
monocwere collected twice from the patient—one 9 months
before her death and the second immediately prior to her
t
a
c
r
d
t
e
f
p
t
1
V
b
p
t
t
h
i
l
P
m
c
T
r
(
m
t
O
l
(
t
n
c
2
m
c
s
p
a
c
h
s
w
o
M
e
f
w
i
a
S
q
a
w
p
(
D
A
t
i
R
f
s
p
t
b
l
s
T
H
e
s
m
w
117PATHOGENIC MECHANISMS IN HIV COINFECTIONdeath in 1994. No autopsy material was available from
the patient.
Proviral DNA extraction, PCR, and cloning
PBMC were isolated from blood by gradient centrifu-
gation using Ficoll–Hypaque (Pharmacia, Sweden).
Genomic DNA was extracted from 5 3 106 fresh PBMC of
he patient using the Qiagen (Qiagen, Germany) blood kit
s per the manufacturer’s protocol. Nested PCR amplifi-
ation of the HIV env V3 region, env gp120, env C2–V5
egion, and the Vpr gene was carried out as previously
escribed (Wang et al., 1997). Cloning into PGEM-T vec-
or (Promega, Madison, WI) and transformation in Esch-
richia coli (JM 109 strain) were done as per the manu-
acturers’ protocols. Plasmid DNA was extracted from
ositive clones and sequenced by the dideoxy chain
ermination method as previously described (Wang et al.,
997).
iral culture and expansion
The isolation of viral strains from patient 979 was done
y standard coculture. Viral replication in coculture su-
ernatant was measured by p24 antigen and reverse
ranscriptase (RT) activity assays. HIV-positive superna-
ants were further expanded in PBMC of an HIV-negative
ealthy donor and tested for RT before being used to
nfect monocytes, MDM, T-lymphocytes, and GHOST cell
ines.
reparation and infection of monocytes,
acrophages, and T-lymphocytes
PBMC from healthy donors were separated on a Fi-
oll-Hypaque gradient (Pharmacia). The monocytes and
-lymphocytes from the PBMC suspension were sepa-
ated by countercurrent elutriation as reported previously
Kazazi et al., 1992). The remaining T-lymphocytes from
onocytes were depleted by complement-dependent cy-
otoxicity, using a monoclonal anti-CD3 antibody (anti-
KT3; Ortho Diagnostics) and baby rabbit complement
ysis. Purified monocytes were tested by flow cytometry
Epics profile II; Coulter Electronics). Monocyte prepara-
ions with greater than 98–99% purified cells positive for
onspecific esterase and ,1% positive for T-cells were
onsidered suitable for subsequent infection. A total of
3 106 adherent monocytes were cultured in RPMI 1640
edium supplemented with 10% heat-inactivated fetal
alf serum and 10% heat-inactivated pooled human AB
erum. Monocytes were used for infection after 5 h of
reparation. The monocytes were allowed to differenti-
te for 7 days to macrophages. T-lymphocytes were
ultured in RPMI 1640 medium supplemented with 10%
eat-inactivated fetal calf serum and 10% IL-2 under PHA
timulation for 72 h.Monocytes, MDM, and T-lymphocytes were inoculated
ith cell-free single-passage 979 viral strain at 105 cpmf RT activity/ml for 4 h at 37°C. Infected monocytes,
DM, and T-lymphocytes were washed extensively to
liminate cell-free virus. Cultures were replenished with
resh medium every 3 days and culture supernatants
ere collected for quantification of HIV p24 antigen us-
ng the manufacturer’s standards (Coulter HIV antigen
ssay, Coulter Corp., Miami, FL).
equence analysis, phylogeny, and RIP
The V3 and C2–V5 env regions and Vpr gene se-
uences were aligned using CLUSTAL W (Thompson et
l., 1994; Higgins et al., 1992). Phylogenetic analyses
ere performed with the programs from the PHYLIP
ackage (Felsenstein, 1989), employing neighbor joining
Saitou and Nei, 1987) with 100 bootstrap replications.
ifferent HIV-1 subtypes and strains from a coinfected
ustralian patient (Zhu et al., 1995) were obtained from
he Los Alamos HIV Database for phylogenetic compar-
sons. Detection of recombination was done using the
IP (Los Alamos HIV Database). Consensus sequences
rom group I and group II were used as background
equences that were compared with the clones sus-
ected for recombination. The significant similarities be-
ween the query sequence and each representative
ackground sequence were plotted on the graph. The V3
oop charge for each clone was calculated by using
oftware DNA id 1 1.8 (Fred Dardel, France).
ransmission electron microscopy
Transmission electron microscopy was performed on
IV-1-infected healthy donor PBMC, embedded in Spurr
poxy resin, and polymerized at 70°C for 10 h. Serial
ections were cut at 0.5-mm thickness and stained with
methylene blue. Ultrathin sections were cut on a Reichort
Ultracut E ultramicrotome and stained with 2% uranyl
acetate in 50% ethanol followed by Reynold’s lead citrate.
Grids were examined either with Philips CM10 transmis-
sion electron microscope operated at 80 kV or with
CM120 BioTWIN at 100 kV.
Coreceptor usage using GHOST cells expressing
various chemokine receptors
GHOST cells transfected with the expression vector
for CD4 and CCR1, CCR2b, CCR3, CCR4, CCR5, CXCR4,
BOB, or BONZO were used to elucidate the entry mech-
anisms of laboratory adapted and primary viral strains
from patient 979. CXCR4 usage was confirmed by pas-
saging viral strains into H9 cells (a T-cell line). GHOST
cells were maintained in DMEM with 10% fetal calf se-
rum, puromycin (50–100 mg/ml), hygromycin B (100 mg/
l), and G418 (500 mg/ml). The infection of GHOST cells
as done as previously described (Owen et al., 1998).
P24 antigen-positive GHOST cells were subjected to
genomic DNA extraction for PCR amplification of the V3
region and sequencing.
CC
118 WANG ET AL.Determination of viral phenotype
Infection of the MT-2 cell line was performed to deter-
mine the viral phenotype by assessing the capacity of the
viral strains to induce syncytia formation as previously
described (Wang et al., 1997).
Biological separation of viral strains
The biological separation of group I and II HIV-1
strains was carried out first by coculture with pooled
donor PBMC along with the PBMC from patient 979 and
then passaged in monocytes, MDM, and T-lymphocytes
for 14–21 days using culture conditions discussed previ-
ously. The genotype of the virus from each primary cell
type and GHOST cells were verified by extracting proviral
DNA from different cell types followed by amplifying and
cloning of the env gene V2–V5 region and AluI digestion
of positive clones to verify different groups. Viruses from
these cell types were passaged in the same cell types
several times to confirm the entry of strains. Once a pure
population of the viral strains was obtained, the viruses
were further used in infection and coreceptor usage
assays.
Synergistic interactions between viral strains
Throughout the studies we used the same moi of 10,000
RT per group for infecting various cell types to assess
synergistic interactions between group I and group II. Fol-
lowed by biological segregation of two strains by preferen-
tial selection on monocytes and MDM, or Hos-CCR5/Hos
CXCR41 cells, they were reintroduced independently in
different cell types for assessment of synergistic interac-
tion. The effects of viral strains grown separately and in
combination were compared and the synergism between
them was assessed by recording their pathogenicity on
PBMC using TEM, by measuring p24 antigen titers for
assessing viral replication, and by measuring the popula-
tion ratio of two groups by sequencing viral gene segments
from infected cells. The differences between pathogenic
effects and replication of viruses alone and in combination
accompanied by the shift in population ratios were consid-
ered an indicator of synergistic interaction between group I
and group II viruses.
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